WEBSITE BSE:500674 NSE: SANOFI Inc. Year: 1956 Industry: Pharmaceuticals & Drugs
Last updated: 15:55
Sanofi India Ltd manufactures and trades in capsules and pharmaceutical products in India, Singapore and internationally. It presents pharmaceutical merchandise in diverse therapeutic areas, which include diabetes, cardiology, thrombosis, critical nervous machine, anti-infective, epilepsy, hypersensitive reaction and vitamins, anti-histamines, and minerals and supplements underneath the Lantus, Toujeo, Clexane, Amaryl, Cardace, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands thru independent distributors. The business enterprise ...Read More
Sanofi India Ltd manufactures and trades in capsules and pharmaceutical products in India, Singapore and internationally. It presents pharmaceutical merchandise in diverse therapeutic areas, which include diabetes, cardiology, thrombosis, critical nervous machine, anti-infective, epilepsy, hypersensitive reaction and vitamins, anti-histamines, and minerals and supplements underneath the Lantus, Toujeo, Clexane, Amaryl, Cardace, Targocid, Frisium, Combiflam, DePura, Allegra, and Avil brands thru independent distributors. The business enterprise additionally exports its products. The organisation was formerly called Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Ltd is a subsidiary of Hoechst GmbH. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹9426 Cr.
Stock P/E 30
P/B 11.9
Current Price ₹4092.7
Book Value ₹ 343.5
Face Value 10
52W High ₹6717.5
Dividend Yield 2.86%
52W Low ₹ 3976.4
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|
| Net Sales | 515 | 491 | 469 | 732 | 464 | 524 | 515 |
| Other Income | 16 | 11 | 9 | 7 | 5 | 2 | 6 |
| Total Income | 530 | 501 | 479 | 739 | 468 | 526 | 521 |
| Total Expenditure | 393 | 377 | 370 | 514 | 348 | 404 | 397 |
| Operating Profit | 137 | 124 | 109 | 225 | 121 | 122 | 124 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 9 | 9 | 9 | 10 | 9 | 9 | 10 |
| Exceptional Income / Expenses | 0 | 0 | 0 | -27 | -19 | 0 | 8 |
| Profit Before Tax | 127 | 115 | 99 | 188 | 92 | 113 | 122 |
| Provision for Tax | 46 | 34 | 30 | 52 | 24 | 30 | 31 |
| Profit After Tax | 81 | 81 | 70 | 137 | 68 | 82 | 91 |
| Adjustments | 42 | 71 | 68 | 0 | 35 | 0 | 0 |
| Profit After Adjustments | 123 | 152 | 138 | 137 | 103 | 82 | 91 |
| Adjusted Earnings Per Share | 53.4 | 66 | 59.9 | 59.4 | 44.9 | 35.7 | 39.7 |
| #(Fig in Cr.) | Dec 2023 | Dec 2024 | TTM |
|---|---|---|---|
| Net Sales | 1996 | 2013 | 2235 |
| Other Income | 62 | 17 | 20 |
| Total Income | 2058 | 2030 | 2254 |
| Total Expenditure | 1509 | 1523 | 1663 |
| Operating Profit | 549 | 507 | 592 |
| Interest | 2 | 2 | 0 |
| Depreciation | 37 | 37 | 38 |
| Exceptional Income / Expenses | 18 | -38 | -38 |
| Profit Before Tax | 529 | 431 | 515 |
| Provision for Tax | 164 | 118 | 137 |
| Profit After Tax | 365 | 314 | 378 |
| Adjustments | 238 | 100 | 35 |
| Profit After Adjustments | 603 | 413 | 413 |
| Adjusted Earnings Per Share | 262.1 | 179.7 | 179.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 1% | 0% | 0% | 0% |
| Operating Profit CAGR | -8% | 0% | 0% | 0% |
| PAT CAGR | -14% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -25% | -9% | -12% | -0% |
| ROE Average | 36% | 44% | 44% | 44% |
| ROCE Average | 46% | 59% | 59% | 59% |
| #(Fig in Cr.) | Dec 2023 | Dec 2024 |
|---|---|---|
| Shareholder's Funds | 1015 | 861 |
| Minority's Interest | 0 | 0 |
| Borrowings | 0 | 0 |
| Other Non-Current Liabilities | 1153 | 1208 |
| Total Current Liabilities | 2535 | 2610 |
| Total Liabilities | 4703 | 4679 |
| Fixed Assets | 315 | 313 |
| Other Non-Current Assets | 1257 | 1349 |
| Total Current Assets | 3132 | 3018 |
| Total Assets | 4703 | 4679 |
| #(Fig in Cr.) | Dec 2023 | Dec 2024 |
|---|---|---|
| Opening Cash & Cash Equivalents | 1005 | 395 |
| Cash Flow from Operating Activities | 230 | 462 |
| Cash Flow from Investing Activities | 38 | -19 |
| Cash Flow from Financing Activities | -878 | -392 |
| Net Cash Inflow / Outflow | -610 | 50 |
| Closing Cash & Cash Equivalent | 395 | 284 |
| # | Dec 2023 | Dec 2024 |
|---|---|---|
| Earnings Per Share (Rs) | 262.13 | 179.7 |
| CEPS(Rs) | 174.39 | 152.35 |
| DPS(Rs) | 167 | 117 |
| Book NAV/Share(Rs) | 411.7 | 343.96 |
| Core EBITDA Margin(%) | 23.5 | 23.76 |
| EBIT Margin(%) | 25.58 | 20.97 |
| Pre Tax Margin(%) | 25.5 | 20.9 |
| PAT Margin (%) | 17.59 | 15.2 |
| Cash Profit Margin (%) | 19.35 | 16.98 |
| ROA(%) | 13.74 | 6.69 |
| ROE(%) | 52.72 | 36.1 |
| ROCE(%) | 72.06 | 46.16 |
| Receivable days | 19.77 | 31.98 |
| Inventory Days | 68.22 | 102.89 |
| Payable days | 63.52 | 130.04 |
| PER(x) | 30.78 | 34.06 |
| Price/Book(x) | 19.59 | 17.8 |
| Dividend Yield(%) | 2.07 | 1.91 |
| EV/Net Sales(x) | 9.09 | 6.85 |
| EV/Core EBITDA(x) | 33.06 | 27.17 |
| Net Sales Growth(%) | 168.75 | 0.86 |
| EBIT Growth(%) | 121.74 | -18.35 |
| PAT Growth(%) | 133.79 | -13.96 |
| EPS Growth(%) | 287.11 | -31.45 |
| Debt/Equity(x) | 0 | 0 |
| Current Ratio(x) | 1.24 | 1.16 |
| Quick Ratio(x) | 0.97 | 0.96 |
| Interest Cover(x) | 311.88 | 288.6 |
| Total Debt/Mcap(x) | 0 | 0 |
| # | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 60.4 | 60.4 | 60.4 | 60.4 | 60.4 | 60.4 | 60.4 | 60.4 | 60.4 | 60.4 |
| FII | 6.8 | 6.31 | 6.11 | 5.81 | 5.78 | 5.63 | 5.57 | 5.61 | 5.57 | 5.55 |
| DII | 21.69 | 22.51 | 22.88 | 22.59 | 22.62 | 22.71 | 23.02 | 23.05 | 22.28 | 21.31 |
| Public | 11.11 | 10.78 | 10.61 | 11.2 | 11.2 | 11.26 | 11.01 | 10.94 | 11.75 | 12.74 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.39 | 1.39 | 1.39 | 1.39 | 1.39 | 1.39 | 1.39 | 1.39 | 1.39 | 1.39 |
| FII | 0.16 | 0.15 | 0.14 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 | 0.13 |
| DII | 0.5 | 0.52 | 0.53 | 0.52 | 0.52 | 0.52 | 0.53 | 0.53 | 0.51 | 0.49 |
| Public | 0.26 | 0.25 | 0.24 | 0.26 | 0.26 | 0.26 | 0.25 | 0.25 | 0.27 | 0.29 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2.3 | 2.3 | 2.3 | 2.3 | 2.3 | 2.3 | 2.3 | 2.3 | 2.3 | 2.3 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
